Biotech entity

RP-A501

Product

All 1 tracked stories fall under one category: gene-therapy. Of the tracked stories, 1 of 1 also mention Broadcom, the most common co-covered peer. The 5 average consequence score is below the beat benchmark of 6 in the same window.

Last mentioned: Mar 19, 2026

Entity pulse

Recent coverage · RP-A501

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about RP-A501

All 1 tracked stories fall under one category: gene-therapy. Of the tracked stories, 1 of 1 also mention Broadcom, the most common co-covered peer. The 5 average consequence score is below the beat benchmark of 6 in the same window. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. We currently track 1 Biotech story that mention RP-A501, all published on March 19, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering RP-A501. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Stock Volatility

    RCKT shares decline 4.4% amid sector-wide growth stock pressure and regulatory uncertainty.

  2. SEC Filing 8-K

    Company enters into a new material definitive agreement and terminates a previous facility.

  3. FY 2025 Earnings

    Rocket Pharmaceuticals reports full-year 2025 results and provides pipeline updates.

Stories mentioning RP-A501 1

Gene & Cell Therapy Neutral

Rocket Pharmaceuticals Shares Slide 4.4% Amid Regulatory and Financing Shifts

Rocket Pharmaceuticals (RCKT) shares declined 4.4% on March 19, 2026, as investors weighed a recent shift in the company's financial agreements against ongoing regulatory timelines for its lead gene therapy programs. The drop outpaced broader market movements, reflecting specific volatility in the rare disease gene therapy sector.

2 sources

Source: themarketsdaily.com · dailypolitical.com

RP-A501 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.